 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12 |
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P4 trial: Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel (clinicaltrials.gov) - Jan 6, 2016
P4, N=50, Recruiting, Sponsor: Fundaci
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open, Trial initiation date: PDT-Bact (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=10, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Oct 2015
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open, Combination therapy: Actinic Keratoses Treatment With Metvix (clinicaltrials.gov) - Sep 1, 2015
P3, N=26, Recruiting, Sponsor: University Hospital, Limoges
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- ||||| Ameluz (aminolevulinic acid) / Biofrontera
Enrollment closed, Enrollment change: Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy (clinicaltrials.gov) - Aug 6, 2015
P3, N=277, Active, not recruiting, Sponsor: Biofrontera Bioscience GmbH
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=360 --> 277
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P1 trial: Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration (clinicaltrials.gov) - Jul 29, 2015
P1, N=10, Completed, Sponsor: Galderma R&D
- Cysview (hexaminolevulinate) / Photocure, Ameluz (aminolevulinic acid) / Biofrontera
Enrollment open: Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL (clinicaltrials.gov) - Jul 27, 2015
P1/2, N=99, Recruiting, Sponsor: Joint Authority for P
Recruiting --> Active, not recruiting | N=360 --> 277 Not yet recruiting --> Recruiting
- Ameluz (aminolevulinic acid) / Biofrontera
Enrollment open: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) (clinicaltrials.gov) - Jul 16, 2015
P4, N=70, Recruiting, Sponsor: Joint Authority for P
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ameluz (aminolevulinic acid) / Biofrontera
New P4 trial: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) (clinicaltrials.gov) - Jun 6, 2015
P4, N=70, Not yet recruiting, Sponsor: Joint Authority for P
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Clinical: PDT-Bactério: Effects of Topical Dynamic Phototherapy on the Microbiota of Chronic Wounds (clinicaltrials.gov) - Mar 19, 2015
P=N/A, N=10, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage (clinicaltrials.gov) - Mar 7, 2015
P2, N=60, Completed, Sponsor: Fundaci
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial, Combination therapy: Actinic Keratoses Treatment With Metvix (clinicaltrials.gov) - Feb 27, 2015
P3, N=26, Not yet recruiting, Sponsor: University Hospital, Limoges
- | Cysview (hexaminolevulinate) / Photocure, Ameluz (aminolevulinic acid) / Biofrontera
New P1/2 trial: Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitizers: HAL and BF-200 ALA Versus MAL (clinicaltrials.gov) - Feb 20, 2015
P1/2, N=99, Not yet recruiting, Sponsor: Joint Authority for P
- |||| Ameluz (aminolevulinic acid) / Biofrontera
Trial primary completion date: Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy (clinicaltrials.gov) - Jan 28, 2015
P3, N=360, Recruiting, Sponsor: Biofrontera Bioscience GmbH
Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Nov 2015
- Ameluz (aminolevulinic acid) / Biofrontera
Trial completion, Trial primary completion date: Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) (clinicaltrials.gov) - Dec 6, 2014
P4, N=20, Completed, Sponsor: Joint Authority for P
Trial primary completion date: Jan 2015 --> Nov 2015 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014
- Cysview (hexaminolevulinate) / Photocure, Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial primary completion date: Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL (clinicaltrials.gov) - Dec 5, 2014
P1/2, N=20, Recruiting, Sponsor: Joint Authority for P
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2014 Trial primary completion date: Dec 2015 --> May 2016
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (clinicaltrials.gov) - Sep 29, 2014
P1, N=21, Completed, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Dec 2015 --> May 2016 Active, not recruiting --> Completed
- ||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: COMET2: Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (clinicaltrials.gov) - Sep 12, 2014
P3, N=131, Completed, Sponsor: Galderma
Active, not recruiting --> Completed Recruiting --> Completed
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed: Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage (clinicaltrials.gov) - Jul 17, 2014
P2, N=60, Active, not recruiting, Sponsor: Fundaci
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Ameluz (aminolevulinic acid) / Biofrontera
New P3 trial: Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy (clinicaltrials.gov) - May 19, 2014
P3, N=360, Recruiting, Sponsor: Biofrontera Bioscience GmbH
- Cysview (hexaminolevulinate) / Photocure, Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P1/2 trial: Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL (clinicaltrials.gov) - May 18, 2014
P1/2, N=20, Recruiting, Sponsor: Joint Authority for P
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P2 trial: Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage (clinicaltrials.gov) - May 13, 2014
P2, N=60, Recruiting, Sponsor: Fundaci
- Ameluz (aminolevulinic acid) / Biofrontera
Enrollment open: Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) (clinicaltrials.gov) - Apr 21, 2014
P4, N=20, Recruiting, Sponsor: Joint Authority for P
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P2 trial: Treatment of precursors to skin cancer with photodynamic therapy using a halogen lamp Lys-terapi med halogenlampe til behandling af forstadier til hudkr (EUDRACT) - Mar 16, 2014
P2, N=28, Ongoing, Sponsor: Department of Dermatology D92, Bispebjerg Hospital
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open: Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate (clinicaltrials.gov) - Jan 29, 2014
P4, N=162, Recruiting, Sponsor: Maastricht University Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment change: Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne (clinicaltrials.gov) - Aug 6, 2013
P2, N=150, Completed, Sponsor: PhotoCure
Not yet recruiting --> Recruiting N=190 --> 150
- |||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment open: COMET2: Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (clinicaltrials.gov) - Jul 25, 2013
P3, N=120, Recruiting, Sponsor: Galderma
N=190 --> 150 Not yet recruiting --> Recruiting
- Ameluz (aminolevulinic acid) / Biofrontera
New P4 trial: Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) (clinicaltrials.gov) - Jul 4, 2013
P4, N=20, Recruiting, Sponsor: Joint Authority for P
- |||||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: COMET2: Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses (clinicaltrials.gov) - Mar 28, 2013
P3, N=120, Recruiting, Sponsor: Galderma
- ||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: CoMet: Intra-individual Comparison of Efficacy and Safety of Metvix (clinicaltrials.gov) - Feb 28, 2013
P3, N=100, Completed, Sponsor: Galderma
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: Multicenter, randomized, open clinical trial to establish the effectiveness of of methyl-aminolevulinate 16% (Metivix (EUDRACT) - Jan 21, 2013
P3, N=60, Ongoing, Sponsor: Fundaci
- || Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: A clinical trial to compare the occurrence (or incidence) of the most common fair skin cancer in solid organ transplant recipients (squamous cell carcinoma) and its preliminary stage (actinic keratoses) in two different groups: One group is treated with a fixed combination of a cream followed by exposure to red light and the other group receives liquid nitrogen (cryotherapy) as lesion-directed therapy. (EUDRACT) - Nov 8, 2012
P3, N=70, Ongoing, Sponsor: Charit
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment change: Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (clinicaltrials.gov) - Sep 19, 2012
P1, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed N=50 --> 21
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Enrollment closed: Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer (clinicaltrials.gov) - Sep 19, 2012
P1, N=21, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
N=50 --> 21 Recruiting --> Active, not recruiting
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Trial initiation date: AKtransplant: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients (clinicaltrials.gov) - Sep 5, 2012
P4, N=34, Recruiting, Sponsor: Medical University of Vienna
Recruiting --> Active, not recruiting Initiation date: Apr 2012 --> Sep 2012
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment open: AKtransplant: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients (clinicaltrials.gov) - Sep 5, 2012
P4, N=34, Recruiting, Sponsor: Medical University of Vienna
Initiation date: Apr 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
New P4 trial: AKtransplant: Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients (clinicaltrials.gov) - Feb 22, 2012
P4, N=34, Recruiting, Sponsor: Medical University of Vienna
- Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
Trial completion: Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix (clinicaltrials.gov) - Feb 22, 2012
P4, N=9, Completed, Sponsor: Galderma
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P4 trial: Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate (clinicaltrials.gov) - Dec 12, 2011
P4, N=162, Recruiting, Sponsor: Maastricht University Medical Center
- |||||||||| Metvixia (methyl aminolevulinate hydrochloride 16.8% cream) / Galderma
New P3 trial: CoMet: Intra-individual Comparison of Efficacy and Safety of Metvix (clinicaltrials.gov) - Nov 17, 2011
P3, N=100, Completed, Sponsor: Galderma
- Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
New P4 trial: Imiquimod cream therapy versus photodynamic therapy for actinic keratoses in organ transplant patients (EUDRACT) - Nov 16, 2011
P4, N=30, Ongoing, Sponsor: Medizinische Universit